Trials / Unknown
UnknownNCT03972189
Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC)
Phase II, Open Label, Single Arm Study of the Efficacy and Safety of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC)
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 111 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess efficacy and safety of oral TQ-B3101 administered to patients with Advanced Non-Small Cell Lung Cancer (NSCLC) that confirmed ROS1 positive gene mutation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQ-B3101 | TQ-B3101 300 mg given orally in fasting conditions, twice daily in 28-day cycle. |
Timeline
- Start date
- 2019-07-24
- Primary completion
- 2021-03-01
- Completion
- 2021-03-01
- First posted
- 2019-06-03
- Last updated
- 2019-08-15
Locations
22 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03972189. Inclusion in this directory is not an endorsement.